Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00240305




Registration number
NCT00240305
Ethics application status
Date submitted
16/10/2005
Date registered
18/10/2005
Date last updated
16/03/2009

Titles & IDs
Public title
A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome
Scientific title
A Randomised, Double-Blind, Placebo Controlled, Crossover Dose-Ranging Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome
Secondary ID [1] 0 0
4522AS/0004
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metabolic Syndrome 0 0
Dyslipidemia 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Metabolic disorders
Cardiovascular 0 0 0 0
Other cardiovascular diseases
Blood 0 0 0 0
Other blood disorders
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Rosuvastatin

Treatment: Drugs: Rosuvastatin
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Determine the dose-related effect of treatment with rosuvastatin on production & fractional catabolism of apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II), & on the plasma apoA-I, apoA-II & high-density lipoprotein cholesterol (HDL-C) c
Timepoint [1] 0 0
Secondary outcome [1] 0 0
Determine the dose-related effect of treatment with rosuvastatin on cellular cholesterol efflux,total cholesterol, low-density lipoprotein cholesterol (LDL-C), non-LDL-C, triglyceride & pre1-HDL concentrations,HDL2,HDL3 cholesterol ratio
Timepoint [1] 0 0
Secondary outcome [2] 0 0
Cholesteryl ester transfer protein (CETP) and lecithin:cholesterol acyl transferase (LCAT) activity
Timepoint [2] 0 0
Secondary outcome [3] 0 0
Lathosterol and campesterol, total apolipoprotein B (apoB), nonesterified fatty acids (NEFA) and apolipoprotein C-III (apoC-III) plasma concentrations.
Timepoint [3] 0 0

Eligibility
Key inclusion criteria
- Signed informed consent

- male aged 30 to 70 years of age

- LDL-C <6 mmol/L

- HDL-C =1.2 mmol/L

- at least 2 of the following:

- insulin resistance (fasting glucose >6 mmol/L or insulin >10 mU/L or HOMA score >2.5)

- central obesity (waist circumference >=94 cm).

- plasma triglycerides >=1.7 and <4.5 mmol/L.

- blood pressure >=130/ >=85 mm Hg or on drug treatment for hypertension
Minimum age
30 Years
Maximum age
70 Years
Sex
Males
Can healthy volunteers participate?
Yes
Key exclusion criteria
- LDL cholesterol >=6 mmol/L

- pre-existing or history of cardiovascular disease, diabetes, renal dysfunction,
anaemia, history of significant dyspepsia or gastrointestinal disease

- apolipoprotein genotype E2/E2

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2004
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/05/2006
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 0 0
Research Site - Perth
Recruitment postcode(s) [1] 0 0
- Perth

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to investigate the dose-related effect of treatment with
rosuvastatin on production and fractional catabolism of apolipoprotein A-I (apoA-I) and
apolipoprotein A-II (apoA-II), and on the plasma apoA-I, apoA-II and high-density lipoprotein
cholesterol (HDL-C) concentration.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00240305
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Gerald F. Watts, BSc PhD MD
Address 0 0
University Department of Medicine, Royal Perth Hospital, University of Western Australia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00240305